Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
21.2
Revenue year-on-year change (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending March 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales2,347 Million yen+21.2%
Operating profit159 Million yen-34.1%
Ordinary income152 Million yen-36.4%
Net income92 Million yen-43.8%
Operating profit margin10.4% (three months ended in the second quarter)
Selling, general and administrative expenses1,787 Million yen
Results for the three months of the current quarterRevenue: ¥1,184 million; operating profit: ¥123 million; operating margin: 10.4% (three months ended in the second quarter of the fiscal year ending March 2027)
Full-year earnings forecast
Net Sales
4,975 Million yen
Operating profit
707 Million yen
Ordinary income
674 Million yen
Profit attributable to owners of the parent
434 Million yen
Dividend per share
19 Yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales47.2%
Operating profit22.5%
Ordinary income22.6%
Profit attributable to owners of the parent21.2%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
メディックス on a standalone basis is progressing in line with plan for both revenue and profitBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Increase in salesContributions from the results of Sales Lab and the STA Group, among other factors
B2C revenue decreaseSuspension of transactions with a major customer and other factors arising in the previous fiscal year
B2B revenue increaseNew customer acquisition and expanded transactions with existing customers, among other factors
Data management and other revenue increaseContribution from the results of the STA Group
Continued operating profit declineThe STA Group's business structure weighted toward the second half, and structural improvements aimed at establishing a future earnings base
New initiatives
- Launch of the joint “SaaS Growth Program” for SaaS companies
- Enhancement of advertising planning, operations and proposal services through the use of AI
- Support for Wacom's GA4 measurement environment setup and dashboard implementation
Key KPIsA metric the company considers important as a management benchmark.
- Percentage of total revenue generated by customers with 3 or more years of transactions89.3 %
- AI Initiatives508 Deals
- Persona creation time reduction rate90 % reduction
- Proposal work time reduction rate67 % reduction
- Average reduction rate through the use of AI64 %
Segment results
BtoC
Net Sales
907 Million yen
Year on year against the same period last year-4.4%
BtoB
Net Sales
689 Million yen
Year on year against the same period last year+30.0%
Data management and other
Net Sales
750 Million yen
Year on year against the same period last year+64.2%
Market Size / Share
Overall employee review ranking107th out of 2,766 companies
Ranking for career development environment for people in their 20s19th out of 2,766 companies
Number of employees
396 people
As ofEnd-September 2026
Annual Dividend
¥19 /share
Breakdown
Interim8
End of period11
Payout ratio
34 %
DOEGuideline of approximately 4.0%
Acquisition of treasury shares
Actual purchases¥164 million (fiscal year ending March 2027)
PolicyExecute flexibly in accordance with the share price level
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | 2,347 Million yen (YoY +21.2%) |
| Operating profit | 159 Million yen (YoY -34.1%) |
| Ordinary income | 152 Million yen (YoY -36.4%) |
| Net income | 92 Million yen (YoY -43.8%) |
| Operating profit margin | 10.4% (three months ended in the second quarter) |
| Selling, general and administrative expenses | 1,787 Million yen |
| Results for the three months of the current quarter | Revenue: ¥1,184 million; operating profit: ¥123 million; operating margin: 10.4% (three months ended in the second quarter of the fiscal year ending March 2027) |
| Full-year earnings forecast | Net Sales 4,975 Million yen / Operating profit 707 Million yen / Ordinary income 674 Million yen / Profit attributable to owners of the parent 434 Million yen / Dividend per share 19 Yen |
| Progress against full-year forecast | Net Sales 47.2% / Operating profit 22.5% / Ordinary income 22.6% / Profit attributable to owners of the parent 21.2% |
| Self-assessment against the plan | メディックス on a standalone basis is progressing in line with plan for both revenue and profit |
| Segment results | BtoC Net Sales 907 Million yen / yoy_pct -4.4 / BtoB Net Sales 689 Million yen / yoy_pct 30 / Data management and other Net Sales 750 Million yen / yoy_pct 64.2 |
| Breakdown of Factors Affecting the Change | Increase in sales Contributions from the results of Sales Lab and the STA Group, among other factors / B2C revenue decrease Suspension of transactions with a major customer and other factors arising in the previous fiscal year / B2B revenue increase New customer acquisition and expanded transactions with existing customers, among other factors / Data management and other revenue increase Contribution from the results of the STA Group / Continued operating profit decline The STA Group's business structure weighted toward the second half, and structural improvements aimed at establishing a future earnings base |
| Key KPIs | Percentage of total revenue generated by customers with 3 or more years of transactions 89.3 %, AI Initiatives 508 Deals, Persona creation time reduction rate 90 % reduction, Proposal work time reduction rate 67 % reduction, Average reduction rate through the use of AI 64 % |
| Number of employees | 396 people |
| Annual Dividend | ¥19 /share |
| Payout ratio | 34 % |
| Acquisition of treasury shares | Actual purchases ¥164 million (fiscal year ending March 2027) / Policy Execute flexibly in accordance with the share price level |
| Market Size / Share | Overall employee review ranking 107th out of 2,766 companies / Ranking for career development environment for people in their 20s 19th out of 2,766 companies |
| New initiatives | Launch of the joint “SaaS Growth Program” for SaaS companies, Enhancement of advertising planning, operations and proposal services through the use of AI, Support for Wacom's GA4 measurement environment setup and dashboard implementation |
Items this document does not state (10)
Gross Profit MarginUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to contributions from the results of Sales Lab and the STA Group, among other factors. In the BtoB segment, new customer acquisition and expanded transactions with existing customers contributed to the increase, while in the Data Management and Other segment, the STA Group's consolidated contribution was a growth driver. Operating profit, however, declined due to the STA Group's business structure, which is weighted toward the second half, and the impact of structural improvements aimed at establishing a future earnings base. The BtoC segment continued to be affected by the suspension of transactions with a major customer in the previous fiscal year, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.